NOTE 11 – SUBSEQUENT EVENTS

On July 7, 2011, the Company entered into a consulting agreement for clinical trials and other services to be provided to the Company over a 12 month period.  As compensation, the Company has agreed to issue warrants to purchase 100,000 shares of the Company’s common stock.  The warrants have an exercise price of $0.54 per share, and are exercisable for five years. In addition, the Company has agreed to issue 120,000 warrants to purchase common stock, vesting in equal tranches of 30,000 warrants per quarter. Such warrants will have an exercise price equal to the Company’s market price at the time of each vesting tranche, and be exercisable for a period of five years.